The FDA has given 510(k) clearance for peripheral atherectomy products, Turbo-Tandem and Turbo Elite, from Spectranetics, for the treatment of...
Almirall, S.A. and Eloxx Pharmaceuticals Inc., announced that the companies have entered into an exclusive license agreement for the asset ZKN 013. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN 013, including for the use in orphan dermatological diseases
OptiScan Biomedical Corporation announced that the FDA has granted 510(k) clearance for the OptiScanner 5000 Glucose Monitoring System. The clearance...
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Fluoritop 5000 ppm toothpaste is indicated in adults and adolescents aged 16 years and over. Prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and / or root caries).
Fluoride 5000 ppm Toothpaste is indicated in adults and adolescents aged 16 years and over. Prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and / or root caries).
Management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients with cystic fibrosis aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC)